NK-042

N/A

Report date: 2024/06/04 16:18:04

Base Information

Drug NameNK-042
Drug Alias NameNK-042
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsUpdating
Therapy Area/IndicationsSolid tumoursLupus Erythematosus, SystemicLupus Nephritis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai NK CellTech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai NK CellTech Co LtdGuangdong Provincial People'S HospitalAnhui Provincial Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursLupus Erythematosus, SystemicLupus Nephritis +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A